| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BPIL1 |
| Uniprot No | Q8N4F0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-458aa |
| 氨基酸序列 | MAWASRLGLLLALLLPVVGASTPGTVVRLNKAALSYVSEIGKAPLQRALQVTVPHFLDWSGEALQPTRIRILNVHVPRLHLKFIAGFGVRLLAAANFTFKVFRAPEPLELTLPVELLADTRVTQSSIRTPVVSISACSLFSGHANEFDGSNSTSHALLVLVQKHIKAVLSNKLCLSISNLVQGVNVHLGTLIGLNPVGPESQIRYSMVSVPTVTSDYISLEVNAVLFLLGKPIILPTDATPFVLPRHVGTEGSMATVGLSQQLFDSALLLLQKAGALNLDITGQLRSDDNLLNTSALGRLIPEVARQFPEPMPVVLKVRLGATPVAMLHTNNATLRLQPFVEVLATASNSAFQSLFSLDVVVNLRLQLSVSKVKLQGTTSVLGDVQLTVASSNVGFIDTDQVRTLMGTVFEKPLLDHLNALLAMGIALPGVVNLHYVAPEIFVYEGYVVISSGLFYQS |
| 分子量 | 75.6 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 冻干粉 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人BPIL1蛋白的3篇参考文献示例，信息基于过往相关研究主题模拟整理：
---
1. **文献名称**: *"BPIL1 is a novel immune-related gene involved in bacterial recognition"*
**作者**: Zhang Y, et al.
**摘要**: 该研究鉴定了BPIL1作为LBP/BPI蛋白家族成员，通过重组表达纯化了人源BPIL1蛋白，发现其能结合革兰氏阴性菌脂多糖(LPS)，并抑制炎症因子释放，提示其在先天免疫中的潜在调控作用。
2. **文献名称**: *"Structural and functional characterization of recombinant human BPIL1 protein"*
**作者**: Li H, et al.
**摘要**: 通过X射线晶体学解析了重组BPIL1蛋白的N端结构域，发现其具有典型LBP/BPI家族特征性结构。功能实验表明，该蛋白对大肠杆菌具有选择性抑菌活性，且依赖疏水结构域与细菌膜的相互作用。
3. **文献名称**: *"BPIL1 modulates TLR4 signaling pathway in macrophage via interaction with CD14"*
**作者**: Wang X, et al.
**摘要**: 研究利用重组BPIL1蛋白探讨其免疫调节机制，发现BPIL1通过与CD14受体结合抑制TLR4/NF-κB通路活化，在败血症模型中缓解过度炎症反应，为抗炎治疗提供新靶点。
---
**说明**：以上文献为示例性内容，实际研究中可能存在差异。建议通过PubMed或Web of Science检索最新文献，使用关键词“recombinant BPIL1”、“BPIL1 protein function”进一步验证。
Recombinant human bactericidal/permeability-increasing protein-like 1 (BPIL1) is a secretory protein belonging to the lipid-binding protein (LBP)/BPI family, characterized by a conserved N-terminal bactericidal domain and a C-terminal hydrophobic domain. BPIL1 shares structural homology with bactericidal/permeability-increasing protein (BPI), a potent antimicrobial protein targeting gram-negative bacteria. While BPI primarily neutralizes bacterial lipopolysaccharides (LPS) and enhances phagocyte activity, BPIL1’s exact biological function remains less defined. Studies suggest it may act as a pattern recognition receptor or play regulatory roles in innate immunity, particularly at mucosal surfaces like the oral cavity and gastrointestinal tract.
The recombinant form is typically produced in heterologous expression systems (e.g., E. coli or mammalian cells) for functional and structural studies. Research highlights its potential involvement in inflammatory diseases, infection responses, and cancer progression due to its expression in immune cells and epithelial tissues. However, its interaction partners, signaling pathways, and clinical relevance require further exploration. As a novel immune-related molecule, recombinant BPIL1 serves as a tool to decipher its role in host-pathogen interactions and therapeutic targeting. Recent investigations also propose its diagnostic or prognostic value in chronic inflammation and malignancies, though mechanistic insights are still evolving.
×
